Introduction/Background Patients with BRCA muted tumors exhibit distinct clinical and histopathological characteristics. Patients with ovarian cancer and BRCA mutation are younger, and present with specific tumor spread pattern. In the abdominal cavity, they usually have a higher tumor peritoneal tumor burden as well as bulky lymph nodes, with less frequent ovarian masses. These studies are and do not include other genetic anomalies which are now part of the standard genetic testing.

Methodology Retrospective single institution study including patients treated for stage III-IV ovarian cancer with complete cytoreduction, and available genetic and surgical data. Data collected for this study included genetic data (type of mutation, HRD GIS score) and surgical data (abdominal tumor load measured by the peritoneal cancer index and lymph node spread). Data were analyzed using STATA 15.0.

Results 139 patients were included in the study. 67 patients (48.2%) had HRD, and 42 patients (30.2%) had BRCA mutation. 120 (86.3%) underwent cytoreductive surgery, 82 (59.0%) were treated with neoadjuvant chemotherapy and interval debulking surgery. Median PCI at diagnostic laparoscopy was 15 (range 1–39). There was no significant difference between HRD and HRP patients in peritoneal disease distribution (p 0.99), or in the number of peritoneal regions with bulky disease (p 0.74). Number of metastatic lymph nodes (1, 2 or 3) was similar in both groups (P 0.68), with 14 HRP patients, and 16 HRD patients with more than 3 metastatic nodes.

Conclusion There was no difference in the number of metastatic lymph nodes nor in peritoneal disease distribution according to the PCI between HRD and HRP patients with stage III/IV ovarian cancer. Larger studies are needed to assess the impact of HRD on disease spread.

Disclosures -